2. Induced Disease Models Products Cell Cycle/DNA Damage Apoptosis
  3. Nervous System Disease Models DNA/RNA Synthesis Apoptosis
  4. Neuropathic Pain Models
  5. Oxaliplatin

Oxaliplatine est un inhibiteur de la synthèse d'ADN. Oxaliplatine provoque des dommages de réticulation de l'ADN, empêche la réplication et la transcription de l'ADN et provoque la mort cellulaire. Oxaliplatine inhibe les lignées cellulaires de mélanome humain C32 et G361 en fonction du temps avec des valeurs IC50 de 0,98 μM et 0,14 μM, respectivement. Oxaliplatine induit l'autophagie cellulaire.

Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.

For research use only. We do not sell to patients.

CAS No. : 61825-94-3

Size Price Stock Quantity
5 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg In-stock
500 mg In-stock
1 g In-stock
2 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 216 publication(s) in Google Scholar

Other Forms of Oxaliplatin:

Oxaliplatin Related Antibodies

Top Publications Citing Use of Products

216 Publications Citing Use of MCE Oxaliplatin

In Vivo Efficacy Study
Cell Proliferation/Viability Assay
IF

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Dec 3:78:101179.  [Abstract]

    Oxaliplatin (100 nM-4 μM; 48 h) inhibits CEAhigh (AGS) and CEA-⁠/lo (xhGC1) gastric cancer cells, with IC50 values of 150 nM and 2.2 μM, respectively.

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761.  [Abstract]

    The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin (50 nM)] for 48h.

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64.  [Abstract]

    Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23.  [Abstract]

    Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2020 Nov;14(11):2894-2919.  [Abstract]

    FOLFOX was administered as 6 mg/kg Oxaliplatin two hours before administration of 90 mg/kg Leucovorin and 50 mg/kg 5-Fluorouracil at day 1 and a repeat of 5‐Fluorouracil dosing on day 2. Weight loss of ODC-, CTRL-, and FOLFOX-treated mice over time of mice with DLD1 tumors.

    Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2019 Sep;25(9):1428-1441.  [Abstract]

    Quantification of CD3+IFN-γ+ T cells in lung lobes taken from urethane-induced primary lung cancer models (n = 5 mice for SD group, n = 6 mice for all the other groups). Three coronal sections containing five pulmonary lobes from each mouse near the maximal diameters are quantified. Each dot represents one view field. A representative result from two independent experiments is shown.

    View All DNA/RNA Synthesis Isoform Specific Products:

    View All Isoforms
    RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].

    IC50 & Target

    IC50: DNA synthesis[1]
    In Vitro

    Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1].
    Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2].
    Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Oxaliplatin Related Antibodies

    Cell Viability Assay[1]

    Cell Line: HCC, HCCLM3 and Hep3B cells
    Concentration: 24, 48 and 72 hours
    Incubation Time: 2, 4, 8, 16, 32, 64 and 128 μM
    Result: Decreased cell viability in a dose- and time-dependent manner.

    Cell Cycle Analysis[1]

    Cell Line: HCCLM3 and Hep3B cells
    Concentration: 10 μM
    Incubation Time: 24 hours
    Result: Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).

    Cell Cycle Analysis[1]

    Cell Line: HCCLM3 cells
    Concentration: 10 μM
    Incubation Time: 48 hours
    Result: Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.
    In Vivo

    Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth[1].


    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    1. Induction of acute chemotherapy-induced peripheral neuropathy (CINP)[10][11][12]
    Background
    Oxaliplatin induces acute neuropathic pain through a multifaceted mechanism involving disruption of voltage-gated ion channels, activation of TRP channels, suppression of DNA transcription, mitochondrial dysfunction, and increased generation of reactive oxygen species (ROS)[10].
    Specific Modeling Methods
    Rats: SD rats
    Administration: Oxaliplatin (3, 5, 6 and 10 mg/kg) • i.p. • once
    Rats: SD rats
    Administration: Oxaliplatin (2 mg/kg) • i.p. • once
    Mice: Male CD-1 mice
    Administration: Oxaliplatin (10 mg/kg) • i.p. • once
    Mice: Male C57BL/6 mice
    Administration: Oxaliplatin (3 and 6 mg/kg) • i.p. • once
    Mice: Male BALB/c mice
    Administration: Oxaliplatin (5 mg/kg) • i.v. • once
    Note
    Oxaliplatin working solution is typically prepared in 5% glucose solution.
    Modeling Indicators
    Molecular changes: Activation of TRPA1/TRPM8 channels, voltage-gated Na⁺ channel dysfunction, and mild ROS elevation
    Mechanical allodynia: Decreased paw withdrawal threshold (Von Frey test)
    Cold allodynia: Decreased paw withdrawal latency (acetone test)
    Motor function: No impairment (rotarod test), confirming pain specificity

    2. Induction of chronic chemotherapy-induced peripheral neuropathy (CINP)[10][11][12]
    Background
    Oxaliplatin-induced activation of TRPA1 channels on dorsal root ganglion (DRG) neurons triggers Ca2+ influx, leading to the accumulation of ROS, mitochondrial DNA (mtDNA) damage, disruption of the electron transport chain, and opening of the mitochondrial permeability transition pore (mPTP). These alterations subsequently impede ATP synthesis and promote neurotoxicity[10].
    Specific Modeling Methods
    Rats: SD rats
    Administration: Oxaliplatin (2.4 mg/kg) • i.p. • on days 1-3, 6-10, and 13-15
    Rats: SD rats
    Administration: Oxaliplatin (2 and 4 mg/kg) • i.p. • on days 1, 2, 3, 4, 5
    Rats: SD rats
    Administration: Oxaliplatin (6 mg/kg) • i.p. • on days 1,3, 5, 7
    Rats: SD rats
    Administration: Oxaliplatin (2.4, 3.2, and 4 mg/kg) • i.p. • twice weekly for 4.5 weeks
    Rats: Wistar rats
    Administration: Oxaliplatin (4 mg/kg) • i.p. • twice weekly for 4 weeks
    Rats: Wistar rats
    Administration: Oxaliplatin (6 mg/kg) • i.p. • once per day for 6 days
    Rats: SD rats
    Administration: Oxaliplatin (2 mg/kg) • i.v. • once per day for 5 days
    Mice: C57BL/6J mice; BALB/c mice; ICR mice
    Administration: Oxaliplatin (0.3 and 3 mg/kg) • i.p. • 5 consecutive days, followed by 2 days of rest, for two cycles
    Mice: C57BL/6 mice
    Administration: Oxaliplatin (3 mg/kg) • i.p. • 3 times per week for 4 weeks
    Mice: CD-1 mice
    Administration: Oxaliplatin (2.4 mg/kg) • i.p. • 5 consecutive days each week for 2 weeks
    Mice: Swiss mice
    Administration: Oxaliplatin (6 mg/kg) • i.p. • every 3 days over 6 days
    Note
    Oxaliplatin is typically prepared in 5% glucose solution.
    Modeling Indicators
    Molecular changes: Increased ROS levels, activation of TLR4/NF‑κB pathway (TNF‑α, IL‑1β), decreased ATP, and TRPA1 sensitization
    Histological changes: Significant loss of intraepidermal nerve fibers (IENF) in hind paw skin
    Mechanical allodynia: Decreased paw withdrawal threshold (Von Frey test)
    Cold allodynia: Decreased paw withdrawal latency (acetone test)
    Motor function: No impairment (rotarod test), confirming pain specificity
    Nerve conduction velocity: Decreased sensory nerve conduction velocity (SNCV); normal motor nerve conduction velocity (MNCV)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Nude mice[1]
    Dosage: 5 and 10 mg/kg
    Administration: Intraperitoneal injection; for 32 days
    Result: Reduced tumor volume in HCCLM3 tumor xenografts.
    Clinical Trial
    Molecular Weight

    397.29

    Formula

    C8H14N2O4Pt
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O1)C(O[Pt]21[NH2][C@@H]3CCCC[C@H]3[NH2]2)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    H2O : 2 mg/mL (5.03 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Oxaliplatin's activity)

    DMF : 1.67 mg/mL (4.20 mM; Need ultrasonic; DMSO can inactivate Oxaliplatin's activity)

    Ethanol : < 1 mg/mL (insoluble; DMSO can inactivate Oxaliplatin's activity)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5171 mL 12.5853 mL 25.1705 mL
    5 mM 0.5034 mL 2.5171 mL 5.0341 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  5% w/v Glucose Solution

      Solubility: 3.33 mg/mL (8.38 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.65%

    SDS (419 KB)

    COA (253 KB) HNMR (256 KB) RP-HPLC (239 KB) MS (70 KB) Elemental Analysis Report (110 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMF / H2O 1 mM 2.5171 mL 12.5853 mL 25.1705 mL 62.9263 mL
    H2O 5 mM 0.5034 mL 2.5171 mL 5.0341 mL 12.5853 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Oxaliplatin Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Oxaliplatin61825-94-3DNA/RNA SynthesisApoptosisapoptosisDNA cross-linksDNA-protein cross-linksanticancerInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Oxaliplatin
    Cat. No.:
    HY-17371
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB) Italian - IT (419 KB) Korean - KR (419 KB) Portuguese - PT (419 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.